Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jan;175(1):74-83.
doi: 10.7326/M21-1962. Epub 2021 Nov 30.

Gastric Bypass Versus Sleeve Gastrectomy in Type 2 Diabetes: Effects on Hepatic Steatosis and Fibrosis : A Randomized Controlled Trial

Kathrine Aglen Seeberg  1 , Heidi Borgeraas  2 , Dag Hofsø  3 , Milada Cvancarova Småstuen  4 , Nils Petter Kvan  5 , John Olav Grimnes  5 , Morten Lindberg  6 , Farhat Fatima  7 , Lars Thomas Seeberg  8 , Rune Sandbu  9 , Jøran Hjelmesæth  10 , Jens Kristoffer Hertel  2
Affiliations
Randomized Controlled Trial

Gastric Bypass Versus Sleeve Gastrectomy in Type 2 Diabetes: Effects on Hepatic Steatosis and Fibrosis : A Randomized Controlled Trial

Kathrine Aglen Seeberg et al. Ann Intern Med. 2022 Jan.

Abstract

Background: Weight loss improves fatty liver disease. No randomized trial has compared the effects of sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) on liver fat content and fibrosis.

Objective: To compare the 1-year effects of SG and RYGB on hepatic steatosis and fibrosis.

Design: Single-center, randomized, controlled trial (Oseberg [ObesitySurgery in Tønsberg]). (ClinicalTrials.gov: NCT01778738).

Setting: Tertiary care obesity center in Norway.

Participants: 100 patients (65% female; mean age, 47.5 years; mean body mass index, 42 kg/m2) with type 2 diabetes mellitus (T2DM).

Intervention: From January 2013 to February 2018, patients were randomly assigned (1:1 ratio) to SG or RYGB.

Measurements: The primary outcome was remission of T2DM (previously published). Predefined secondary outcomes in the present study were hepatic steatosis and fibrosis assessed by magnetic resonance imaging (liver fat fraction), enhanced liver fibrosis (ELF) test, noninvasive indices, and liver enzymes.

Results: Liver fat fraction declined similarly after SG (-19.7% [95% CI, -22.5% to -16.9%]) and RYGB (-21.5% [CI, -24.3% to -18.6%]) from surgery to 1-year follow-up, and almost all patients (SG, 94%; RYGB, 100%) had no or low-grade steatosis at 1 year. The ELF score category remained stable in 77% of patients, but 18% experienced worsening of fibrosis at 1 year, with no substantial between-group difference.

Limitations: Single-center study, short follow-up time, and lack of power for secondary outcomes.

Conclusion: With an almost complete clearance of liver fat 1 year after surgery, RYGB and SG were both highly effective in reducing hepatic steatosis. Bariatric surgery had less influence on degree of fibrosis in the short term, but assessment of long-term progression is warranted.

Primary funding source: Vestfold Hospital Trust and the South-Eastern Norway Regional Health Authority.

PubMed Disclaimer

Comment in

Publication types

Associated data